Serum amyloid β protein in young and elderly depression: A pilot study

Psychogeriatrics

Volumn 9, Issue 4, 2009, Pages 180-185

  Kita, Yohei ^a   Baba, Hajime ^a   Maeshima, Hitoshi ^b   Nakano, Yoshiyuki ^b   Suzuki, Toshihito ^b   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Juntendo University Hospital   (Japan)

Author keywords

A ; Alzheimer's; Amyloid; Dementia; Depression; Serum.

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUPS BY AGE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATHOLOGY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMYLOID BETA-PROTEIN; DEPRESSIVE DISORDER, MAJOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PILOT PROJECTS; REFERENCE VALUES;

EID: 77954443604     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/j.1479-8301.2009.00293.x     Document Type: Article

References (28)

1. Devanand DP, Sano M, Tang MX. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 1996, 53:175-182.
2. Wilson RS, Barnes LL, Mendes de Leon CF. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology 2002, 59:364-370.
3. Ownby RL, Crocco E, Acevedo A. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006, 63:530-538.
4. Geerlings MI, den Heijer T, Koudstaal PJ. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 2008, 70:1258-1264.
5. Suzuki N, Cheung TT, Cai XD. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994, 264:1336-1340.
6. Shinotoh H, Suhara T. Beyond PIB: The next generation of amyloid-imaging ligands. Psychogeriatrics 2008, 8:105-107.
7. Schröder J, Pantel J, Ida N. Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging. Mol Psychiatry 1997, 2:505-507.
8. Andreasen N, Minthon L, Davidsson P. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001, 58:349-350.
9. Takeda M, Morihara T, Okochi M. Mild cognitive impairment and subjective cognitive impairment. Psychogeriatrics 2008, 8:155-160.
10. Graff-Radford NR, Crook JE, Lucas J. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007, 64:354-362.
11. Xu W, Kawarabayashi T, Matsubara E. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Brain Res 2008, 1219:169-179.
12. van Oijen M, Hofman A, Soares HD. Plasma Abeta (1-40) and Abeta (1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006, 5:655-660.
13. Rapp MA, Schnaider-Beeri M, Grossman HT. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 2006, 63:161-167.
14. Pomara N, Doraiswamy PM, Willoughby LM. Elevation in plasma Abeta42 in geriatric depression: a pilot study. Neurochem Res 2006, 31:341-349.
15. Qiu WQ, Sun X, Selkoe DJ. Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry 2007, 22:536-342.
16. Sun X, Mwamburi DM, Bungay K. Depression, antidepressants, and plasma amyloid beta (beta) peptides in those elderly who do not have cardiovascular disease. Biol Psychiatry 2007, 62:1413-1417.
17. Sun X, Steffens DC, Au R. Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry 2008, 65:542-550.
18. Saito H, Ichikawa K, Nomiyama T. Changes in activities of daily living during treatment of late-life depression. Psychogeriatrics 2008, 8:12-18.
19. Inoue K, Tanii H, Kaiya H. Possible therapeutic effect of clonazepam upon elderly depressive patients. Psychogeriatrics 2007, 7:33-36.
20. Leroux MC, Kemp R. Effect of a companion dog on depression and anxiety levels of elderly residents in a long-term care facility. Psychogeriatrics 2009, 9:23-26.
21. Yamagata B, Tomioka H, Takahashi T. Differentiating early and late-onset depression with multichannel near-infrared spectroscopy. Psychogeriatrics 2008, 8:79-87.
22. Konishi K, Hori K, Oda T. Effects of aging on behavioral symptoms in Alzheimer's disease. Psychogeriatrics 2009, 9:11-16.
23. Lockwood KA, Alexopoulos GS, van Gorp WG. Executive dysfunction in geriatric depression. Am J Psychiatry 2002, 159:1119-1126.
24. Murphy CF, Gunning-Dixon FM, Hoptman MJ. White-matter integrity predicts stroop performance in patients with geriatric depression. Biol Psychiatry 2007, 61:1007-1010.
25. Alexopoulos GS, Meyers BS, Young RC. Clinically defined vascular depression. Am J Psychiatry 1997, 15:562-565.
26. Ertekin-Taner N, Graff-Radford N, Younkin LH. Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees. Genet Epidemiol 2001, 21:19-30.
27. Pákáski M, Bjelik A, Hugyecz M. Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. Neurochem Int 2005, 47:190-195.
28. Nelson RL, Guo Z, Halagappa VM. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol 2007, 205:166-176.